JP7394768B2 - キナーゼ阻害剤としての環状イミノピリミジン誘導体 - Google Patents

キナーゼ阻害剤としての環状イミノピリミジン誘導体 Download PDF

Info

Publication number
JP7394768B2
JP7394768B2 JP2020538750A JP2020538750A JP7394768B2 JP 7394768 B2 JP7394768 B2 JP 7394768B2 JP 2020538750 A JP2020538750 A JP 2020538750A JP 2020538750 A JP2020538750 A JP 2020538750A JP 7394768 B2 JP7394768 B2 JP 7394768B2
Authority
JP
Japan
Prior art keywords
mmol
compound according
pharmaceutically acceptable
compound
quinazolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020538750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534373A (ja
JP2020534373A5 (enExample
Inventor
チェン チェン
Original Assignee
エイビーエム セラピューティックス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイビーエム セラピューティックス コーポレイション filed Critical エイビーエム セラピューティックス コーポレイション
Publication of JP2020534373A publication Critical patent/JP2020534373A/ja
Publication of JP2020534373A5 publication Critical patent/JP2020534373A5/ja
Application granted granted Critical
Publication of JP7394768B2 publication Critical patent/JP7394768B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2020538750A 2017-09-20 2018-09-20 キナーゼ阻害剤としての環状イミノピリミジン誘導体 Active JP7394768B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762561142P 2017-09-20 2017-09-20
US62/561,142 2017-09-20
PCT/US2018/052047 WO2019060611A1 (en) 2017-09-20 2018-09-20 CYCLIC IMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF KINASES

Publications (3)

Publication Number Publication Date
JP2020534373A JP2020534373A (ja) 2020-11-26
JP2020534373A5 JP2020534373A5 (enExample) 2021-11-04
JP7394768B2 true JP7394768B2 (ja) 2023-12-08

Family

ID=64457074

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020538750A Active JP7394768B2 (ja) 2017-09-20 2018-09-20 キナーゼ阻害剤としての環状イミノピリミジン誘導体

Country Status (10)

Country Link
US (2) US11254680B2 (enExample)
EP (1) EP3684772B1 (enExample)
JP (1) JP7394768B2 (enExample)
KR (1) KR102796209B1 (enExample)
CN (1) CN111247152B (enExample)
AU (1) AU2018338098B2 (enExample)
BR (1) BR112020005455A2 (enExample)
CA (1) CA3076202A1 (enExample)
MX (1) MX2020003126A (enExample)
WO (1) WO2019060611A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3684772B1 (en) * 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
TWI817018B (zh) 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
EP4161907A1 (en) 2020-06-09 2023-04-12 Array BioPharma Inc. 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
JP2023538521A (ja) * 2020-08-07 2023-09-08 エイビーエム セラピューティックス コーポレイション キナーゼ阻害剤およびその使用
CN114380697A (zh) * 2021-11-30 2022-04-22 上海毕得医药科技股份有限公司 一种n-甲基乙基胺盐酸盐的制备工艺
TW202409040A (zh) 2022-07-19 2024-03-01 大陸商西藏海思科製藥有限公司 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途
CN117209503B (zh) * 2023-09-13 2025-10-17 苏州翔实医药发展有限公司 一种5,6-二氢咪唑并[1，2-c]喹唑啉及其衍生物合成的方法
WO2025108405A1 (zh) * 2023-11-22 2025-05-30 西藏海思科制药有限公司 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途
WO2025153057A1 (zh) * 2024-01-17 2025-07-24 海思科医药集团股份有限公司 一种含braf抑制剂的药物组合物及其在医药上的应用
WO2025176185A1 (zh) * 2024-02-23 2025-08-28 海思科医药集团股份有限公司 一种braf抑制剂的制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
JP2013545768A (ja) 2010-12-02 2013-12-26 ユーアイ カンパニー リミテッド 新規なピュリニルピリジニルアミノ−２，４−ジフルオロフェニルスルホンアミド誘導体、その薬学的に許容可能な塩、その製造方法及びそれを有効成分として含むＲａｆキナーゼの阻害活性を有する薬学的組成物
JP2014503573A (ja) 2011-01-27 2014-02-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング セリン／スレオニンキナーゼ阻害薬としての新規ピリミド［５，４−ｄ］ピリミジルアミノフェニルスルホンアミド
WO2014047648A1 (en) 2012-09-24 2014-03-27 Neupharma, Inc. Certain chemical entities, compositions, and methods
US20150158854A1 (en) 2013-12-11 2015-06-11 Development Center For Biotechnology Quinazoline compounds, method for preparing the same and use thereof
WO2016010662A1 (en) 2014-07-16 2016-01-21 Development Center For Biotechnology Quinoxaline compounds, method for preparing the same and use thereof
CN105272970A (zh) 2014-07-03 2016-01-27 中国药科大学 基于色原酮结构的Raf激酶抑制剂及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE511510T1 (de) * 2002-09-30 2011-06-15 Bayer Schering Pharma Ag Kondensierte azol-pyrimidin-derivate
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
RU2469036C2 (ru) 2007-06-01 2012-12-10 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Имидазопиридиновые ингибиторы киназ
BRPI0814423B1 (pt) 2007-07-17 2022-04-19 Plexxikon, Inc Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos
EP2348020A1 (en) 2009-12-23 2011-07-27 Esteve Química, S.A. Preparation process of erlotinib
US8889741B2 (en) 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
KR20150054833A (ko) * 2012-09-14 2015-05-20 이터니티 바이오사이언스 인코퍼레이티드 단백질 키나제 억제제로서의 아미노이소퀴놀린 유도체
EP3684772B1 (en) * 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013545768A (ja) 2010-12-02 2013-12-26 ユーアイ カンパニー リミテッド 新規なピュリニルピリジニルアミノ−２，４−ジフルオロフェニルスルホンアミド誘導体、その薬学的に許容可能な塩、その製造方法及びそれを有効成分として含むＲａｆキナーゼの阻害活性を有する薬学的組成物
JP2014503573A (ja) 2011-01-27 2014-02-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング セリン／スレオニンキナーゼ阻害薬としての新規ピリミド［５，４−ｄ］ピリミジルアミノフェニルスルホンアミド
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
WO2014047648A1 (en) 2012-09-24 2014-03-27 Neupharma, Inc. Certain chemical entities, compositions, and methods
US20150158854A1 (en) 2013-12-11 2015-06-11 Development Center For Biotechnology Quinazoline compounds, method for preparing the same and use thereof
CN105272970A (zh) 2014-07-03 2016-01-27 中国药科大学 基于色原酮结构的Raf激酶抑制剂及其制备方法和用途
WO2016010662A1 (en) 2014-07-16 2016-01-21 Development Center For Biotechnology Quinoxaline compounds, method for preparing the same and use thereof

Also Published As

Publication number Publication date
WO2019060611A1 (en) 2019-03-28
JP2020534373A (ja) 2020-11-26
BR112020005455A2 (pt) 2020-09-24
CA3076202A1 (en) 2019-03-28
MX2020003126A (es) 2020-10-01
US11254680B2 (en) 2022-02-22
CN111247152A (zh) 2020-06-05
EP3684772C0 (en) 2023-12-06
US11932647B2 (en) 2024-03-19
EP3684772A1 (en) 2020-07-29
US20200247813A1 (en) 2020-08-06
RU2020113707A3 (enExample) 2021-12-23
AU2018338098A1 (en) 2020-05-07
US20220251089A1 (en) 2022-08-11
KR102796209B1 (ko) 2025-04-16
KR20200055034A (ko) 2020-05-20
CN111247152B (zh) 2024-07-16
RU2020113707A (ru) 2021-10-20
EP3684772B1 (en) 2023-12-06
AU2018338098B2 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
JP7394768B2 (ja) キナーゼ阻害剤としての環状イミノピリミジン誘導体
RU2686323C2 (ru) Новые соединения и композиции для ингибирования fasn
CN113214287B (zh) Hpk1抑制剂及其使用方法
TW202144338A (zh) 嘧啶并二環類衍生物、其製備方法及其在醫藥上的應用
BR112019012239A2 (pt) compostos de aminotiazol como inibidores de c-kit
HUE029275T2 (en) Phthalazinone ketone derivative, method of preparation and therapeutic use
WO2012000304A1 (zh) 杂环炔苯类化合物及其药用组合物和应用
CN106187915A (zh) 具有alk与egfr双重活性的抑制剂及其制备方法和应用
TWI523856B (zh) BCR-ABL kinase inhibitor and its application
TWI669300B (zh) 嘧啶類衍生物、其製備方法、其藥物組合物以及其在醫藥上的用途
WO2014079232A1 (zh) 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用
KR20220028075A (ko) 티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도
TWI565698B (zh) 喹啉化合物，其製造方法及用途
TWI691500B (zh) 作為tyro3、axl和mertk(tam)家族受體酪胺酸激酶抑制劑之雜環化合物
JP2023554391A (ja) キナーゼ阻害剤およびそれらの使用
KR20170095243A (ko) Pi3kbeta 저해제로서의 헤테로사이클릴 연결된 이미다조피리다진 유도체
RU2801302C2 (ru) Производные циклического иминопиримидина в качестве ингибиторов киназ
CN114853746A (zh) 甲酰胺类化合物、其制备方法及其在医药上的应用
HK40031627A (en) Cyclic iminopyrimidine derivatives as kinase inhibitors
HK40031627B (zh) 作为激酶抑制剂的环状亚氨基嘧啶衍生物
CN110461827A (zh) 作为PI3K-β抑制剂的喹喔啉和吡啶并吡嗪衍生物
TW202320767A (zh) 雜芳基衍生物parp抑制劑及其用途
TW202408509A (zh) 雜芳基衍生物的藥物組合物及其在醫藥上的應用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200629

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210921

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230810

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230821

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231030

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231128

R150 Certificate of patent or registration of utility model

Ref document number: 7394768

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150